Practice-changing results in NSCLC are expected


At ESMO Congress 2019, phase III FLAURA trial is one of the much awaited studies in lung cancer, according to Alessandra Curioni Fontecedro, University Hospital Zürich, Switzerland and Associate Editor of the Daily Reporter. Overall survival data will be presented at the first Presidential Symposium at the congress on Saturday 28 September. 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.